Administration of anti-CSF1R antibody failed to significantly alter tumor growth or change the CTL infiltration (online supplemental figure S5E, F), despite a pronounced decrease in the average frequency of tumor-infiltrating F4/80hi TAMs by 61% in YUMM3.3-Ctrl, or by 86% in -βΑ tumors, respectively (online supplemental figure S5G). The gene discussed is CSF1R; the disease is neoplasm.